MktsMarkets

NewAmsterdam Pharma Company N.V.
NASDAQ: NAMSKey statistics
NAMS News
Stories mentioning NAMS from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 3,040 | 32.00 | 348.00 | 19,145 | 2,978 | 12,772 | 29,111 | 2,279 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 38,009 | 38,594 | 30,971 | 27,516 | 44,751 | 34,895 | 35,702 | 38,379 |
| Sales General & Admin | 23,451 | 27,418 | 24,520 | 27,264 | 27,152 | 21,106 | 18,412 | 16,475 |
| Total Operating Expenses | 61,460 | 66,012 | 55,491 | 54,780 | 71,903 | 56,001 | 54,114 | 54,854 |
| Operating Income (Loss) | (58,420) | (65,980) | (55,143) | (35,635) | (68,925) | (43,229) | (25,003) | (52,575) |
| Interest Income | 5,650 | 6,473 | 6,713 | 7,055 | 7,351 | 4,485 | 4,443 | 4,870 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (48,441) | (74,923) | (72,005) | (17,364) | (39,527) | (92,177) | (16,648) | (39,007) |
| Tax Provision | (1.00) | |||||||
| Net Income (Loss) | (48,441) | (74,923) | (72,005) | (17,364) | (39,527) | (92,177) | (16,647) | (39,007) |
| Earnings Per Share (Basic) | (0.40) | (0.63) | (0.61) | (0.15) | (0.34) | (0.98) | (0.18) | (0.41) |
| Earnings Per Share (Diluted) | (0.40) | (0.63) | (0.61) | (0.15) | (0.34) | (0.98) | (0.18) | (0.41) |
| Weighted Average Shares Outstanding (Basic) | 121,716 | 118,424 | 119,000 | 118,556 | 116,125 | 94,358 | 94,754 | 94,712 |
| Weighted Average Shares Outstanding (Diluted) | 121,716 | 118,424 | 119,000 | 118,556 | 116,125 | 94,358 | 94,754 | 94,712 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About NAMS
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is a stock listed on the Nasdaq Stock Market under the ticker symbol NAMS. It last traded at $19.71 (Oct 23, 2026, 4:00 PM ET), down 8.7% on the day. That gives NewAmsterdam Pharma a market capitalisation of $2.6B.
Over the past 52 weeks NAMS has traded between $19.58 and $42.20.
Revenue for the quarter ended Mar 31, 2026 was $3.0M; a net loss of $48.4M. Revenue was up 2.1% from $3.0M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $3.0M | -$48.4M | -1593.5% |
| Dec 31, 2025 | $32.0K | -$74.9M | -234134.4% |
| Sep 30, 2025 | $348.0K | -$72.0M | -20691.1% |
| Jun 30, 2025 | $19.1M | -$17.4M | -90.7% |
From NewAmsterdam Pharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…